Navigation Links
Oncothyreon to present at Rodman Renshaw Global Healthcare Conference
Date:9/3/2009

SEATTLE, WA, Sept. 3 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) (TSX: ONY) announced today that Robert Kirkman, M.D., President and Chief Executive Officer, will present at the Rodman Renshaw 11th Annual Healthcare Conference taking place Sept. 9-11, 2009 in New York.

Dr. Kirkman will present at 2 p.m. Eastern Time on Thursday, Sept. 10. A live and archived webcast of the presentation will be accessible at http://www.wsw.com/webcast/rrshq15/onty or by visiting the Oncothyreon website www.oncothyreon.com under the "News Events" section.

About Oncothyreon

Oncothyreon is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Oncothyreon's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients. For more information, visit www.oncothyreon.com.


'/>"/>
SOURCE Oncothyreon Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Biomira announces plan to change name to Oncothyreon
2. Oncothyreon highlights corporate and clinical objectives for 2008
3. Oncothyreon to present at BIO CEO & Investor Conference
4. Oncothyreon launches new corporate website
5. Oncothyreons PX-478 is effective in preclinical model of human lung cancer
6. Oncothyreon announces March 10th webcast of fourth quarter and full year financial results conference call
7. Oncothyreon reports full year and fourth quarter 2007 financial results
8. Oncothyreon to present at upcoming investment conferences
9. Oncothyreon announces issuance of patent for PX-867
10. Oncothyreon announces effectiveness of shelf registration statement
11. Oncothyreon announces data from multiple small molecule programs to be presented at American Association of Cancer Research Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... 2014 Industry leaders from ... engage around the theme, ,Commercial Opportunities in the Era ... Elsevier , a world-leading provider of ... host a gathering of some of the industry,s most ... healthcare today and in the future. The ...
(Date:9/30/2014)... German . , ... demonstrated a new kind of building block for digital ... could be based on three-dimensional arrangements of nanometer-scale magnets ... the semiconductor industry CMOS fabrication of silicon chips ... at the University of Notre Dame are exploring "magnetic ...
(Date:9/30/2014)... , Sept. 30, 2014 Report Details ... with highest potential revenues Do you want to ... gives you revenue predictions for those biological drugs ... therapies you find financial data, R&D trends, opportunities ... get sales forecasts to 2024 at overall world ...
(Date:9/30/2014)... Over the last decade, the laboratory filtration ... budgets and increased acceptance of new filtration technologies in ... industries are also catalyzing the growth of laboratory filtration ... to grow at a strong CAGR during the forecast ... $2,532.6 million by 2019. The market is mainly driven ...
Breaking Biology Technology:Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 2Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 3A new dimension for integrated circuits: 3-D nanomagnetic logic 2A new dimension for integrated circuits: 3-D nanomagnetic logic 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 2Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 4Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 5Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 2Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 3Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 4Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 5
... 29 Tutogen Medical, Inc.,(Amex: TTG ), a ... (allograft) and animal (xenograft) tissue, announced today,that Guy L. ... the Roth Capital Partners New York Investor Conference on,Thursday, ... conference is,being held at The Westin NY at Times ...
... N.Y., Aug. 29 Emisphere,Technologies, Inc. (Nasdaq: ... been appointed to the position of Chief Financial ... CFO and Interim Chief Executive Officer,of Astralis, Ltd., ... Michael V. Novinski, President and Chief Executive Officer. ...
... PHRM ) today announced that the U.S. ... designation for oral Azacitidine in the,treatment of Myelodysplastic ... to facilitate the development and,expedite the review of ... or,life-threatening conditions and that demonstrate the potential to ...
Cached Biology Technology:Tutogen Medical, Inc. to Present at the Roth Capital Partners 2007 New York Conference 2Emisphere Technologies, Inc. Appoints Michael R. Garone chief financial officer 2Emisphere Technologies, Inc. Appoints Michael R. Garone chief financial officer 3Pharmion's Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes 2Pharmion's Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes 3Pharmion's Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes 4Pharmion's Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes 5Pharmion's Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes 6
(Date:9/30/2014)... team of environmental scientists and engineers, led by ... a three-year, $5.25 million grant from the U.S. ... Research to make a direct positive impact on ... and disposal of radioactive contaminants. , "Understanding the ... dealing with environmental aspects of nuclear technologies is ...
(Date:9/30/2014)... New England Journal of Medicine reports positive ... drug crizotinib against the subset of lung cancer marked ... study of 50 patients with advanced non-small cell lung ... rate was 72 percent, with 3 complete responses and ... it takes for the disease to resume its growth ...
(Date:9/30/2014)... in German . ... expensive foods in the world. Because they grow underground, people ... distinctive smell of truffles is not only of interest to ... direction of the Goethe University Frankfurt have discovered that the ... which are trapped inside truffle fruiting bodies. , White truffles ...
Breaking Biology News(10 mins):Researchers get $5.25 million to advance nuclear technologies in South Carolina 2NEJM: Crizotinib effective in Phase 1 trial against ROS1 lung cancer 2On the trail of the truffle flavor 2
... team of University of Washington undergraduate students was among ... one of the Bill & Melinda Gates Foundation,s $100,000 ... fifth round of Grand Challenges Explorations, an initiative to ... unproven ways to improve health in developing countries. To ...
... release is available in Spanish . , U.S. ... ways to improve soil on degraded land so it can ... with USDA,s Agricultural Research Service (ARS) at the agency,s Appalachian ... constructed or replacement subsoils and topsoils to build better and ...
... Albert Einstein College of Medicine of Yeshiva University researcher ... Honor in Basic Science from the American Cancer Society ... role the tumor microenvironment plays in modulating cancer behavior, ... cells called macrophages play both in normal development and ...
Cached Biology News:Undergraduates' low-cost ultrasound system wins Gates Foundation grant 2Undergraduates' low-cost ultrasound system wins Gates Foundation grant 3Improving soil for better lawns and gardens 2Einstein researcher receives American Cancer Society Medal of Honor 2
Mouse monoclonal [SPM217] to Secretory Component Glycoprotein ( Abpromise for all tested applications)....
Mouse monoclonal [3G8] to MDMA ( Abpromise for all tested applications)....
Shh Antibody Shipping Temperature: HOT Storage Temperature: -20C...
Anti-Cohesin (Scc1/Rad21) Monoclonal Antibody Research Focus: signal transduction Storage: -20C Shipping Temperature: +4C...
Biology Products: